Aeterna Zentaris (TSE:AEZS) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aeterna Zentaris has completed its Phase 3 DETECT-trial for macimorelin, a diagnostic test for Childhood Onset Growth Hormone Deficiency, with the last patient visit taking place in Europe. The study, which enrolled 100 subjects, is on track to report findings in Q3 2024. This achievement is a significant step for the company, potentially extending macimorelin’s use to pediatric diagnostics.
For further insights into TSE:AEZS stock, check out TipRanks’ Stock Analysis page.
